NOVOCURE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.64 USD | +3.31% |
|
+4.51% | -15.37% |
Chart calendar NovoCure Limited
ca1c7f16e7e9073560c46623eb734f2.XltcqLPHQ2I7JE3JTRLcLxq8JljXpGhz_xDw8MDKT1E.LgFonYakdAF5HBSMfUCmWnb0YwiunVwlmWeGqfmBCQ46LGvC-IwVDgwUGA~974db7981f05a63b2e72f99be89f2b53
Upcoming events on NovoCure Limited
Past events on NovoCure Limited
| 27/03/2024 05:30 pm | METIS Phase 3 Results Call |
| 22/02/2024 06:30 pm | Q4 2023 Earnings Call |
| 22/02/2024 05:30 pm | Q4 2023 Earnings Release |
| 10/01/2024 09:00 pm | JPMorgan Healthcare Conference |
| 30/11/2023 02:00 am | Piper Sandler Healthcare Conference - Fireside Chat |
| 18/11/2023 10:05 pm | Society for Neuro Oncology Meeting |
| 18/11/2023 09:36 am | Society for Neuro Oncology Meeting |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - Prolonged |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - Molecular characterization |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - Development of Tumor |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - Tumor Treating Fields |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - Adopting Tumor |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - The pivotal TRIDENT |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - The pivotal METIS |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - Investigating safety |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - Advanced MRI |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - Distant progression |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - Real world experience |
| 18/11/2023 09:00 am | Society for Neuro Oncology Meeting - Long-term global |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 351 351 0.05% | 494 494 0.14% | 535 539 -0.81% | 538 537 0.15% | 509 509 -0.01% | 538 |
|
EBITDA Million USD | Released Forecast Spread | 7,55 9,20 -17.93% | 39,6 40,3 -1.87% | -34,1 -20,6 -65.7% | -78,9 -43,7 -80.45% | -222 -233 4.77% | -223 |
|
EBIT Million USD | Released Forecast Spread | -0,91 6,79 -113.45% | 30,4 34,9 -12.99% | -44,3 -28,8 -53.83% | -89,5 -77,0 -16.3% | -233 -246 5.21% | -225 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -8,82 -2,12 -316.03% | 18,1 25,8 -29.93% | -52,1 -36,7 -41.76% | -81,8 -79,7 -2.67% | -192 -208 7.72% | -178 |
|
Net income Million USD | Released Forecast Spread | -7,23 -10,5 31.43% | 19,8 28,8 -31.23% | -58,4 -41,1 -41.81% | -92,5 -88,0 -5.13% | -207 -217 4.38% | -189 |
|
EPS USD | Released Forecast Spread | -0,07 -0,10 31.95% | 0,20 0,26 -23.66% | -0,56 -0,41 -37.32% | -0,88 -0,82 -6.68% | -1,95 -2,02 3.64% | -1,76 |
| Announcement Date | 27/02/20 | 25/02/21 | 24/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 133 134 -0.95% | 138 134 2.42% | 141 135 4.25% | 131 133 -1.79% | 128 127 0.75% | 122 128 -4.49% | 126 124 1.45% | 127 129 -1.12% | 134 134 -0.01% | 131 | 134 | 136 | 138 | 140 |
|
EBITDA Million USD | Released Forecast Spread | -20,7 -4,23 -389.63% | 1,80 -20,3 108.87% | -18,5 -11,6 -59.56% | -22,0 -23,8 7.88% | -40,3 -24,4 -64.79% | -57,5 -36,2 -58.72% | -59,9 -54,6 -9.7% | -55,4 -60,5 8.34% | -49,0 -59,1 17.12% | -59,0 | -58,4 | -56,3 | -49,1 | -59,9 |
|
EBIT Million USD | Released Forecast Spread | -23,4 -7,85 -198.13% | -0,81 -18,4 95.63% | -21,1 -12,9 -63.63% | -24,6 -25,8 4.65% | -43,0 -29,1 -47.83% | -60,2 -35,5 -69.72% | -62,7 -60,2 -4.15% | -58,2 -65,5 11.12% | -51,7 -64,6 19.94% | -53,8 | -55,6 | -57,3 | -58,7 | -62,8 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -25,6 -10,2 -151.37% | -2,52 -22,1 88.63% | -23,4 -15,7 -48.36% | -23,4 -28,9 18.94% | -32,6 -30,5 -6.76% | -51,1 -35,5 -43.89% | -53,9 -51,0 -5.71% | -48,2 -56,8 15.1% | -38,5 -54,7 29.49% | -41,4 | -43,5 | -45,6 | -47,3 | -54,1 |
|
Net income Million USD | Released Forecast Spread | -26,5 -11,1 -138.47% | -4,65 -19,9 76.69% | -24,0 -15,6 -53.44% | -26,6 -28,9 7.94% | -37,3 -32,8 -13.79% | -53,1 -37,9 -40.18% | -57,4 -52,2 -9.94% | -49,5 -56,0 11.65% | -47,1 -56,6 16.75% | -45,1 | -46,5 | -48,0 | -49,2 | -54,1 |
|
EPS USD | Released Forecast Spread | -0,25 -0,11 -133.95% | -0,04 -0,19 79.32% | -0,23 -0,14 -59.3% | -0,25 -0,28 9.18% | -0,36 -0,31 -15.31% | -0,50 -0,34 -47.06% | -0,54 -0,50 -8% | -0,46 -0,53 12.38% | -0,45 -0,52 13.7% | -0,42 | -0,43 | -0,45 | -0,45 | -0,44 |
| Announcement Date | 24/02/22 | 28/04/22 | 28/07/22 | 27/10/22 | 23/02/23 | 04/05/23 | 27/07/23 | 26/10/23 | 22/02/24 | - | - | - | - | - |
| 29/04/2024 | SHENZHEN YHLO BIOTECH CO., LTD.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | INARI MEDICAL, INC.: Q1 2024 Earnings Release |
| 02/05/2024 | IRADIMED CORPORATION: Q1 2024 Earnings Release |
| 02/05/2024 04:30 pm | NOVOCURE LIMITED: Q1 2024 Earnings Release |
| 06/05/2024 | SHOCKWAVE MEDICAL, INC.: Q1 2024 Earnings Release |
| 07/05/2024 01:39 am | SI-BONE, INC.: Q1 2024 Earnings Release |
| 08/05/2024 01:35 am | MASIMO CORPORATION: Q1 2024 Earnings Release |
| 08/05/2024 01:35 am | TREACE MEDICAL CONCEPTS, INC.: Q1 2024 Earnings Release |
| 08/05/2024 01:35 am | PENUMBRA, INC.: Q1 2024 Earnings Release |
| 08/05/2024 | CHEMOMETEC A/S: Q3 2024 Earnings Release |
Past sector events for NovoCure Limited
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- NVCR Stock
- Calendar NovoCure Limited
